Tourmaline Bio, Inc. (TRML)
Automate Your Wheel Strategy on TRML
With Tiblio's Option Bot, you can configure your own wheel strategy including TRML - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TRML
- Rev/Share 0.0016
- Book/Share 10.0638
- PB 4.7293
- Debt/Equity 0.0006
- CurrentRatio 24.6757
- ROIC -0.395
- MktCap 1222736977.0
- FreeCF/Share -3.3508
- PFCF -14.1683
- PE -13.8548
- Debt/Assets 0.0005
- DivYield 0
- ROE -0.305
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | TRML | Chardan Capital Markets | -- | Buy | -- | $70 | April 23, 2025 |
| Initiation | TRML | Wedbush | -- | Outperform | -- | $42 | March 6, 2025 |
| Initiation | TRML | BMO Capital Markets | -- | Outperform | -- | $50 | Dec. 6, 2024 |
News
TOURMALINE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Tourmaline Bio, Inc. - TRML
Published: September 11, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Tourmaline Bio, Inc. (NasdaqGS: TRML) to Novartis AG. Under the terms of the proposed transaction, shareholders of Tourmaline will receive $48.00 in cash for each share of Tourmaline that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequat.
Read More
NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline
Published: September 10, 2025 by: Zacks Investment Research
Sentiment: Neutral
Novartis is set to acquire Tourmaline Bio for $1.4B, adding late-stage anti-IL-6 candidate pacibekitug to its cardiovascular pipeline.
Read More
This Small Biotech Stock Is Surging Today. Here's Why.
Published: September 09, 2025 by: Investopedia
Sentiment: Positive
Tourmaline Bio (TRML) shares have had a strong run this year. News that Swiss pharma giant Novartis (NVS) is buying the small biotech firm for $1.4 billion to complement its cardiovascular pipeline is giving Tourmaline a fresh boost.
Read More
Wall Street Analysts Predict a 151% Upside in Tourmaline Bio, Inc. (TRML): Here's What You Should Know
Published: August 15, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 151% upside potential for Tourmaline Bio, Inc. (TRML). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Tourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 Inhibition
Published: May 20, 2025 by: Seeking Alpha
Sentiment: Positive
Pacibekitug showed statistically significant hs-CRP reduction in CKD patients in the phase 2 TRANQUILITY study, establishing proof-of-concept for IL-6 inhibition. Positive data supports advancing pacibekitug to a phase 3 cardiovascular outcomes trial for ASCVD, pending an FDA meeting in late 2025. The 7 major Atherosclerotic Cardiovascular Disease markets are expected to reach $30.6 billion by 2035.
Read More
About Tourmaline Bio, Inc. (TRML)
- IPO Date 2021-05-07
- Website https://www.tourmalinebio.com
- Industry Biotechnology
- CEO Sandeep C. Kulkarni
- Employees 74